Clinical Trial Update: A Safety Assessment of Oral Letermovir in Infants With Symptomatic Congenital Cytomegalovirus [Phase 1]

View source ↗

Summary

A Phase 1 safety assessment of oral letermovir in infants with symptomatic congenital cytomegalovirus infection is underway.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Cytomegalovirus Infection

Drugs mentioned

• PREVYMIS (letermovir)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Congenital Cytomegalovirus Infection | Phase 1 | Status: RECRUITING